RC-BMAC

基本信息

批准号：
10221537
负责人：
TOREN FINKEL
金额：
$ 13.42万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-09-30 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10221537
关键词：
Adoption Aging American Animal Model Animals Area Back Basic Science Biological Biological Markers Biological Models Biological Process Biological Products Biological Sciences Biology Biology of Aging CRISPR screen Capsicum Chemicals Clinical Clinical Trials Clustered Regularly Interspaced Short Palindromic Repeats Collaborations Complement Consultations Core Facility Development Doctor of Philosophy Drosophila genus Elderly Equilibrium Faculty Fostering Foundations Funding Future Gait Genes Genetic Geriatrics Geroscience Goals Human Impairment Individual Inflammation Institutes International Intervention Investments Knowledge Laboratories Language Leadership Link Medical Methodology Mission Molecular Molecular Target Muscle function Muscle satellite cell Neurosciences Organism Pharmacology Phenotype Pilot Projects Pre-Clinical Model Process Reagent Research Personnel Research Support Research Training Resources Rodent Science Scientist System Techniques Technology Translating Translations Visit Work Zebrafish age related base biomarker development clinical care clinical practice design exosome first-in-human gene therapy healthspan high throughput analysis high throughput screening improved innovation insight instrumentation member metabolomics microbiome molecular drug target molecular targeted therapies muscle physiology novel novel marker novel therapeutics pre-clinical preservation prevent recruit screening single-cell RNA sequencing small molecule libraries square foot targeted treatment tool translational study trend whole genome

项目摘要

BMAC Summary/Abstract: The impact of basic science is increasingly influencing medical practice. This trend will likely only accelerate in the near future, as techniques including gene therapy and CRISPR-based gene editing begin to impact clinical care. The continued progress of this approach, and its application to geriatrics, requires a seamless integration of basic, translational and clinical researchers. In order to facilitate this integration, we are proposing creation of a new Core for this application. Entitled, the Biology of Mobility and Aging Core (BMAC), this Core will foster the work of clinicians and basic scientists by linking the tenets of `geroscience' to advance new treatments to improve balance and mobility. These include the identification of new biomarkers, elucidating new molecular targets for drug therapy, using in-depth animal phenotyping to assess new biologic agents, and generally promoting back and forth translation between human and basic studies. This work will ultimately help catalyze the ability of our Pepper Center to conduct first-in-human clinical trials of novel agents to preserve mobility and balance in late life. Excitingly, some of these efforts have already been initiated. By supporting pilot, developmental, and external projects, the BMAC also enhances the rigor, strength and quality of our OAIC. Moreover, BMAC resources that include state-of-the-art instrumentation and methodologies, a range of seminars and didactics, as well as laboratory visits, unique genetic reagents and in-depth consultations, will become widely and easily accessible to Pepper investigators. The BMAC includes internationally renowned faculty members who constitute a group of senior investigators with knowledge spanning neuroscience, muscle physiology, pre-clinical animal phenotyping, metabolomics, translational pharmacology, the microbiome and high throughput genetic and chemical screening platforms. All BMAC faculty operate state-of-the-art and well- funded laboratories in areas relevant to the biology of mobility and aging.

BMAC摘要/摘要：基础科学的影响越来越多地影响医学实践。这种趋势可能只会加速不久的将来，随着包括基因疗法和基于CRISPR的基因编辑在内的技术开始影响临床关心。这种方法的持续进展及其在老年医学上的应用需要无缝整合基础，翻译和临床研究人员。为了促进这种整合，我们正在提议创建该应用程序的新核心。该核心将促进流动性和衰老核心的生物学（BMAC），该核心将促进临床医生和基础科学家的工作通过将“ Geroscience”的原则联系起来，以将新的治疗方法推向提高平衡和流动性。这些包括识别新的生物标志物，阐明新分子药物治疗的靶标，使用深入的动物表型来评估新的生物学剂，并且通常在人类和基础研究之间来回促进。这项工作最终将有助于催化我们的胡椒中心进行新型药物的首次人类临床试验的能力，以保留移动性和晚年的平衡。令人兴奋的是，其中一些努力已经开始。通过支持飞行员发展性和外部项目，BMAC还提高了我们OAIC的严格，力量和质量。此外，包括最先进的仪器和方法论在内的BMAC资源，一系列研讨会和教学品以及实验室访问，独特的遗传试剂和深入的咨询将辣椒调查人员可以广泛易于使用。 BMAC包括国际知名构成一群具有神经科学知识的高级调查员的教师生理学，临床前动物表型，代谢组学，转化药理学，微生物组和高通量遗传和化学筛选平台。所有BMAC的教师都经营最先进的教师在与流动性和衰老生物学有关的领域的资助实验室。